Skip to content

Comparison of helicobacter pylori eradication rate with quadriple therapy containing gemifloxacin versus clarithromycin in patients with h.pylori infection

Comparison of helicobacter pylori eradication rate with quadriple therapy containing gemifloxacin versus clarithromycin in dyspeptic patients referring to Rasool Akram Hospital 2013

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012102011054N2
Enrollment
140
Registered
2013-04-21
Start date
2013-04-06
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Capsule omeprazole 20mg? tablet bismuth subsalisylate 262mg?1gr Capsule amoxicillin 2times per dat(BD) Capsule gemifloxacin320mg one per day for 10 days. Intervention 2: Capsule omep
Treatment - Drugs
Capsule omeprazole 20mg? tablet bismuth subsalisylate 262mg?1gr Capsule amoxicillin 2times per dat(BD) Capsule gemifloxacin320mg one per day for 10 days
Capsule omeprazole 20mg , Tablet bismuth subsalisylat 262mg?500mg Capsule clarithromycin? Capsule amoxicillin 1gr 2times per day(BD)for 10 days

Sponsors

Vice chancellor for research,Tehran University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria : Age older than 18 years Exclusion criteria: previous history of any treatment of h.pylori infection ? severe underlying diseases (renal failure, cirrhosis, congestive heart failure - cardiac, gastric surgery, any type of cancer) ?sensitivity to drugs which is used in study? taking any antibiotics by patients in 4 weeks before the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Helicobacterpylori infecetion. Timepoint: 8 weeks following end of treatment. Method of measurement: UBT.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Nikbakht

Colorectal Resaerch Center, Raso0lakaram Hospital,Tehran University of Medical Sciences

hajarnik@yahoo.co.uk+98 21 6435 2358

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026